Erratum to "dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: a narrative review and discussion of research needs" [obesity pillars 11C (2024)100121]
Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects
We have been increasingly hearing concerns from healthcare facilities about a class of medications known as glucagon-like peptide-1 receptor (GLP-1) agonists and their impact on patients receiving anesthesia for procedures
Gastrointestinal side effects affect up to 40% of patients beginning GLP-1 therapy, with gas and bloating ranking among the most common complaints during the first 48 weeks of treatment
While trends change quickly, the fundamentals remain: fair odds, fast payouts, and excellent support
Significantly, it lowers the volume of food noiseintense food cravings for sugary, fatty, and processed foods, making it easier to make healthier food choices